Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Clinical Pharmacology in Drug Development
|
April 29, 2016
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Manish Gupta, Bei Wang, Timothy J Carrothers, et al.
Journal of Clinical Pharmacology
|
September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
Manish Gupta, Patricia M Lorusso, Bei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2013
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Sara A Hurvitz, Luc Dirix, Judit Kocsis, et al.
Current Drug Metabolism
|
April 6, 2012
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer
Dan Lu, Howard A Burris, Bei Wang, et al.
Current Drug Metabolism
|
April 6, 2012
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism
Ben-Quan Shen, Daniela Bumbaca, Ola Saad, et al.
Cancer Chemotherapy and Pharmacology
|
January 25, 2012
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish, Manish Gupta, Bei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ranjana H Advani, Daniel Lebovic, Andy Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
Howard A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
The Lancet. Oncology
|
May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Blood
|
December 3, 2016
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Steven R Leong, Siddharth Sukumaran, Maria Hristopoulos, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Clinical Pharmacology in Drug Development
|
April 29, 2016
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Manish Gupta, Bei Wang, Timothy J Carrothers, et al.
Journal of Clinical Pharmacology
|
September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
Manish Gupta, Patricia M Lorusso, Bei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2013
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Sara A Hurvitz, Luc Dirix, Judit Kocsis, et al.
Current Drug Metabolism
|
April 6, 2012
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer
Dan Lu, Howard A Burris, Bei Wang, et al.
Current Drug Metabolism
|
April 6, 2012
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism
Ben-Quan Shen, Daniela Bumbaca, Ola Saad, et al.
Cancer Chemotherapy and Pharmacology
|
January 25, 2012
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish, Manish Gupta, Bei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ranjana H Advani, Daniel Lebovic, Andy Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
Howard A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
The Lancet. Oncology
|
May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Blood
|
December 3, 2016
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Steven R Leong, Siddharth Sukumaran, Maria Hristopoulos, et al.
Page
of 3